Rethinking the approach to cancer
Nu.Q™ represents a powerful step-change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.
Nu.Q™’s unique technology looks for very early ‘nucleosomic’ markers of cancer
Nu.Q™ uses an array of simple, cost-effective, and accurate blood tests
These tests identify early stage cells before the cancer spreads
Giving medical professionals increased diagnostic power
Early diagnosis informs and reassures patient
Nu.Q™ can reduce the strain on over-burdened healthcare systems
How it works
Cancer leads to irregular levels of uniquely structured nucleosomes in the blood. A nucleosome is a section of DNA wrapped around a core of proteins. Through a simple test, with less than a drop of blood, we are able to detect those unique nucleosomes; and by measuring and analyzing them, our Nu.Q™ tests can establish whether cancer is present in the patient.
Volition’s initial Nu. Q™ products are focusing on colorectal cancer. Colorectal cancer is ranked second among all newly diagnosed cancers.
Patients with bowel cancer caught early (at stage I) have an average 97% five-year survival rate. Currently, fewer than one in ten people are diagnosed at stage I
If colorectal cancer is not caught until it has spread (stage IV), the chances of surviving five years or more falls to just 7%
Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide
In response to the findings on the benefits of early diagnosis, the EU and numerous other countries worldwide have mandated colorectal cancer screening programs. There are currently organised colorectal cancer screening programmes in 14 of the 28 EU states, with a further 10 states offering some form of public or privately accessible screening.
Colorectal Cancer Screening Triage Test
Volition’s first Nu.Q™ test is the Nu.Q™ colorectal cancer screening triage test. This test works in conjunction with the current standard screening test, the fecal immunochemical test (FIT), used in most colorectal cancer screening programs.
The triage test has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer
Streamlining the diagnostic process
The Nu.Q™ colorectal cancer screening triage test identifies patients who have received a false positive result on their FIT test. Approximately 95% of people who receive a positive FIT score do not have colorectal cancer due to the test’s detecting blood in stool, not cancer directly. Therefore, the Nu.Q™ colorectal cancer screening triage test aims to streamline the diagnostic process and ensure that fewer patients are referred for unnecessary colonoscopies.
Our expert team
The Research Team based in Namur bring together years of scientific experience with the passion that is commonplace at Volition. Using their extensive knowledge, the team is dedicated to developing diagnostic tools that will relieve the burden of cancer worldwide; for the patients, the clinical teams and the healthcare systems.
Our Scientific Advisory Board brings together a unique combination of world leaders in the fields of epigenetics, clinical oncology and clinical diagnostics. Together they bring insights, share opinions and act as a knowledgeable sounding board to help us develop our technology and products to meet real clinical needs in line with the very latest scientific thinking.
Our Executive Team are a collective force of distinct individuals but our aim is the same – to save lives by revolutionizing the way cancer is diagnosed.
Our Board of Directors have decades of entrepreneurial, managerial and leadership experience. They are responsible for our strategy, activities, risk management and financial performance.